Humana Shares Fall as 600,000-Member Medicare Pullback Challenges Recovery

Humana shares came under pressure after the health insurer outlined plans to withdraw from Medicare Advantage markets affecting roughly 600,000 members in 2027, highlighting the difficult balance between protecting profitability and maintaining enrollment growth.

Humana’s stock closed Friday at $385.54, down about 1.8%, as investors weighed the potential impact of the planned exits on the company’s broader turnaround strategy. The move is part of Humana’s effort to improve the profitability of its Medicare Advantage business after rising medical costs and funding pressures weighed on margins.

The company expects to recapture approximately 40% of the members affected by the withdrawals through other Humana plans. That would leave a modeled net membership reduction of roughly 360,000 people, although the final impact will depend on how members respond during the annual enrollment period.

Profitability Takes Priority

Humana has increasingly shifted its Medicare Advantage strategy away from enrollment growth at any cost and toward improving returns. The insurer plans to withdraw from lower-performing plans and markets while placing greater emphasis on products with stronger profitability and value-based care arrangements.

The company has set a goal of achieving a sustainable pre-tax margin of at least 3% by 2028. Executives have indicated that the 2027 plan changes are intended to make progress toward that target by improving the economics of its Medicare Advantage portfolio.

The planned exits come after a period of significant membership growth. Humana added more than 1 million Medicare Advantage members for 2026 coverage and has continued to expand its presence even as other major insurers have pulled back.

Earnings Show Mixed Picture

Humana’s second-quarter results provided investors with some encouraging signs. The company reported approximately $40.9 billion in revenue, up 26% year over year, while adjusted earnings per share reached $7.61, exceeding analyst expectations. Humana also maintained its full-year adjusted earnings guidance of at least $9 per share.

However, pressure on the company’s underlying Medicare Advantage economics remains a concern. Lower Star Ratings are expected to reduce quality-related bonus payments, contributing to a weaker GAAP earnings outlook. Humana lowered its full-year GAAP earnings guidance to at least $6.52 from a previous minimum of $8.36.

The Road Ahead

The 2027 Medicare Advantage exits underscore the challenges facing Humana as it attempts to rebuild margins while preserving its competitive position. The company will need to balance membership retention, pricing, medical-cost management and improvements in its Medicare Star Ratings.

For investors, the key question is whether sacrificing a portion of enrollment can generate enough improvement in profitability to put Humana firmly on track toward its 2028 margin objective.

With roughly 600,000 members affected by the latest withdrawals, the coming enrollment cycle could provide an important test of whether Humana’s strategy can deliver stronger financial performance without undermining its position in the Medicare Advantage market.

Source: ts2.tech